PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

The agency gave the green light to a U.S. company manufacturing Augmentin XR, an antibiotic first approved more than two ...

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...

The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

A high-stakes meeting with wide-ranging public health implications again didn’t result in a vote, as members struggled to ...

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...

Weeks after being named head of CDER, Pazdur has submitted paperwork to step down at the end of the month, exacerbating ...